Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Operating Leases: 2019-2023

Historic Operating Leases for Heron Therapeutics (HRTX) over the last 5 years, with Dec 2023 value amounting to $2.8 million.

  • Heron Therapeutics' Operating Leases rose 49.43% to $780,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $780,000, marking a year-over-year increase of 49.43%. This contributed to the annual value of $2.8 million for FY2023, which is 49.08% down from last year.
  • Latest data reveals that Heron Therapeutics reported Operating Leases of $2.8 million as of FY2023, which was down 49.08% from $5.5 million recorded in FY2022.
  • Over the past 5 years, Heron Therapeutics' Operating Leases peaked at $14.6 million during FY2020, and registered a low of $2.8 million during FY2023.
  • For the 3-year period, Heron Therapeutics' Operating Leases averaged around $5.4 million, with its median value being $5.5 million (2022).
  • In the last 5 years, Heron Therapeutics' Operating Leases grew by 18.94% in 2020 and then tumbled by 49.08% in 2023.
  • Heron Therapeutics' Operating Leases (Yearly) stood at $12.2 million in 2019, then increased by 18.94% to $14.6 million in 2020, then tumbled by 45.09% to $8.0 million in 2021, then slumped by 31.23% to $5.5 million in 2022, then plummeted by 49.08% to $2.8 million in 2023.